Allos Therapeutics, Inc. (Nasdaq: ALTH) announced that the FDA has granted fast track designation to the Company's unique next-generation antifolate ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE